Related Experiment Video
Updated: Sep 13, 2025
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
SLC4A11 is a targetable marker correlated with therapeutic responses in ovarian cancer
Xin Li1,2, Jia Yuan1,2, Fanchen Wang1,2
1Research Center for Clinical Medicine, Jinshan Hospital, Fudan University, 1508 Longhang Road, Shanghai, 201508, China.
Background:
Solute carrier family 4 member 11 (SLC4A11) is involved in borate homeostasis, metabolism reprogramming, cell growth, and cell adhesion. However, the biological function of SLC4A11 in ovarian cancer (OC) is still unclear. This study explores the anti-tumor and biological activities of SLC4A11 in OC.
Methods:
The expression and function of SLC4A11 were evaluated in human OC cells and xenograft mice. SLC4A11 expression was evaluated using data from the TCGA-OV, GTEx, and GEO datasets. The genetic status of SLC4A11 was analyzed by the cBioPortal database. The data of expressional abundance, immunochemistry, and immunofluorescence were analyzed through the HPA database. The correlation between SLC4A11 and immune responses was analyzed with the CIBERSORT database, whereas therapeutic responses were analyzed with the CellMiner database.
Results:
SLC4A11 was found to be highly expressed in OC tissues/cells and had a relationship with an unfavorable prognosis in patients with OC. The overexpressed SLC4A11 promoted OC cell proliferation, migration, and invasion. Reducing SLC4A11 caused the cell cycle arrest at the G0/G1 phase and triggered apoptosis. The in vivo study with a xenographic model revealed that the knockdown of SLC4A11 suppressed tumor growth. Subsequent bioinformatics analyses revealed that SLC4A11 expression was associated with immune responses and therapeutic drug sensitivity.
Conclusions:
These findings have illustrated the oncogenic role of SLC4A11 in OC. SLC4A11 is overexpressed and is correlated with poor prognosis in OC. SLC4A11 may be a targetable biomarker and has a potential value of application in treating patients with OC.
Insights
Solute carrier family 4 member 11 (SLC4A11) is highly expressed in ovarian cancer, promoting tumor growth and poor prognosis. Targeting SLC4A11 may offer a new therapeutic strategy for ovarian cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Solute carrier family 4 member 11 (SLC4A11) plays roles in borate homeostasis, metabolism, cell growth, and adhesion.
- The specific function of SLC4A11 in ovarian cancer (OC) remains largely unexplored.
- This study investigates the anti-tumor and biological functions of SLC4A11 in the context of OC.
Purpose of the Study:
- To elucidate the role of SLC4A11 in ovarian cancer development and progression.
- To evaluate SLC4A11 as a potential biomarker and therapeutic target in OC.
Main Methods:
- Analysis of SLC4A11 expression in human OC tissues and cell lines using TCGA, GTEx, and GEO datasets.
- Functional studies in OC cells and xenograft mice to assess the impact of SLC4A11 modulation.
- Bioinformatic analyses to correlate SLC4A11 with immune responses and drug sensitivity.
Main Results:
- SLC4A11 is significantly overexpressed in OC tissues and cells, correlating with unfavorable patient prognosis.
- Overexpression of SLC4A11 enhances OC cell proliferation, migration, and invasion.
- SLC4A11 knockdown induces G0/G1 cell cycle arrest, apoptosis, and suppresses tumor growth in vivo.
- SLC4A11 expression is linked to immune cell infiltration and sensitivity to certain therapeutic agents.
Conclusions:
- SLC4A11 exhibits an oncogenic role in ovarian cancer.
- High SLC4A11 expression is associated with poor prognosis in OC patients.
- SLC4A11 represents a potential targetable biomarker for OC treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:39lncRNA - Long Non-coding RNAs